# Neurology (epilepsy) Consultation

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Fyodor Dostoevsky (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI018-SYN
- Date: 2026-03-03
- Fictional facility: St. Posthumous Health Center
- Fictional author: Viktor Halvorsen, MD
- Calendar frame: modern shifted

- Requested by: Agnes Lindahl, MD

## Reason for consultation

Recurrent generalized convulsive seizures for many years, never treated, in a 43-year-old man new to the practice. Please confirm the diagnosis, classify the seizures and the epilepsy, review the EEG and MRI, and advise on antiseizure medicine, monitoring, and safety counseling. **S**

## History

Mr. Dostoevsky, a 43-year-old writer, is seen at the request of Dr. Lindahl. He has had generalized convulsive seizures since early adulthood, never treated, now every four to six weeks. Most are unwitnessed; those described to him by bystanders are generalized tonic-clonic, lasting one to two minutes, with tongue biting and hours of confusion afterwards. He recalls no aura and no focal features, and he has had no myoclonic jerks, absences, or seizures in clusters. The most recent, three weeks ago, followed a night without sleep. Sleep loss is the clearest trigger. He has gambling disorder in early treatment and mild depressive and anxiety symptoms. He lives alone and does not drive. **S**

## Examination

| System | Finding |
|---|---|
| Mental status | Alert, oriented, fluent, and articulate; good recall |
| Cranial nerves | Normal, with no nystagmus |
| Motor | Normal bulk, tone, and strength |
| Reflexes | Symmetric; plantar responses flexor |
| Coordination and gait | Normal finger-nose and heel-shin testing; normal gait and tandem walk |
| Mouth | Healing bite mark on the left side of the tongue |

BP 120/76 mmHg; pulse 72 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 68.4 kg; BMI 23.7 kg/m². All vital signs are synthetic.

## Data reviewed

Dr. Lindahl's first-visit note and laboratory results; the routine EEG with photic stimulation and hyperventilation, which is normal with no epileptiform discharges; and the epilepsy-protocol MRI, which is normal with no hippocampal sclerosis, cortical malformation, or other lesion. 

## Assessment

1. **Epilepsy of unknown type** (G40.909). Epilepsy is confirmed by many unprovoked seizures more than 24 hours apart; a normal EEG and MRI do not exclude it. Under the ILAE classification the seizures are generalized tonic-clonic seizures of unknown onset and the epilepsy is of unknown type, with unknown cause, because neither the history nor the tests show whether the seizures begin focally or in both hemispheres. A sleep-deprived EEG may still clarify this. Treatment is clearly indicated, because the recurrence risk is high and every generalized tonic-clonic seizure carries a risk of injury and of SUDEP. **S**
2. **Choice of antiseizure medicine**. For an epilepsy of unknown type the medicine should work for both focal and generalized seizures. Valproate is the most effective for generalized and unclassified epilepsy, but it causes weight gain, tremor, and liver and metabolic effects. Levetiracetam starts quickly but can cause irritability and low mood, a concern with his depressive symptoms and gambling. Lamotrigine is effective and well tolerated, has mood-stabilizing effects, and is not an enzyme inducer, but it must be increased slowly to lower the risk of a serious rash. After discussion he chose lamotrigine. **S**
3. **Safety and SUDEP**. Living alone, sleeping irregularly, and having uncontrolled generalized tonic-clonic seizures, some at night, are the main SUDEP risk factors. Good seizure control lowers the risk most. **S**
4. **Gambling disorder and mood in relation to his epilepsy** (F63.0). Nights at the tables mean lost sleep and missed doses, so his gambling and his seizures share triggers. Depression and anxiety are common in epilepsy, and all antiseizure medicines carry a warning about suicidal thoughts, which matters more because gambling disorder raises suicide risk. Lamotrigine has no interaction with the treatments planned for his gambling. **S**

## Recommendations

1. Start lamotrigine today: 25 mg daily for two weeks, 50 mg daily for two weeks, 50 mg twice daily for one week, 75 mg twice daily for one week, then 100 mg twice daily; primary care to check for rash at each dose step.
2. Stop lamotrigine and seek care the same day for any rash, mouth sores, fever, or swollen glands.
3. Sleep-deprived EEG in about three weeks.
4. A lamotrigine trough level once at steady state as his reference, and again only after a breakthrough seizure, if nonadherence is suspected, or when an interacting medicine is started; no routine blood count or liver tests on lamotrigine.
5. No rescue medicine now, because his seizures are single and brief; review if they become prolonged or come in clusters.
6. Bone health: vitamin D is adequate and lamotrigine is not an enzyme inducer, so no DXA scan.
7. A seizure diary, regular sleep with no writing through the night, little alcohol, and pill organizer and phone alarms for adherence.
8. No driving until he has been seizure-free for a sustained period and I have reviewed him; showers rather than baths, no swimming or climbing alone, and care with stoves and sharp tools.
9. SUDEP discussed today; a written seizure action plan for friends, who should call 911 for a seizure lasting more than five minutes, repeated seizures, injury, or seizures in water.
10. PHQ-9 and a suicide-risk review in primary care at each visit; continue gambling-disorder treatment.
11. Neurology review in about ten months, in January, or sooner after any breakthrough seizure; primary care manages the titration and monitoring in between.

## Strengths and supports

- Engagement in care and meaningful activity **S**

## Communication

Discussed with Dr. Lindahl, who sees him the same day and will start the titration. The diagnosis, the choice of medicine, the rash warning, and SUDEP were explained to Mr. Dostoevsky, who agreed with the plan and received the titration schedule and seizure action plan in writing. **S**

## Follow-up

Neurology review in January, or sooner after any breakthrough seizure; results of the sleep-deprived EEG to be sent to Dr. Lindahl. **S**

## Guideline basis

- Evidence-based guideline: Management of an unprovoked first seizure in adults: Report of the Guideline Development Subcommittee of the American Academy of Neurology and the American Epilepsy Society (2015), American Academy of Neurology and American Epilepsy Society (Neurology)
- Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy (2018), American Academy of Neurology and American Epilepsy Society (Neurology)
- Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology (2017), International League Against Epilepsy (Epilepsia)
- ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology (2017), International League Against Epilepsy (Epilepsia)
- Practice guideline summary: Sudden unexpected death in epilepsy incidence rates and risk factors (2017), American Academy of Neurology and American Epilepsy Society (Neurology)
- The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy (2021), The Lancet
- ILAE clinical practice recommendations for the medical treatment of depression in adults with epilepsy (2022), International League Against Epilepsy (Epilepsia)
